Category Business

Miist Therapeutics

Medications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments

Medications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments Medications Miist Therapeutics, a trailblazing company focused on the development of physics-based inhaled medicines, has announced that it has secured $7 million in seed funding from a group…

Read MoreMedications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments
Pharmaceuticals

Tonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer

Tonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer Tonix Pharmaceuticals Holding a fully integrated biopharmaceutical company specializing in the development and commercialization of innovative therapies for pain management and other health challenges, has announced the promotion of Siobhan Fogarty…

Read MoreTonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer
AdvanCell

AdvanCell Closes Oversubscribed $112M Series C Funding

AdvanCell Closes Oversubscribed $112M Series C Funding AdvanCell, a pioneering clinical-stage radiopharmaceutical company focused on developing groundbreaking cancer therapeutics, has announced the successful closure of an oversubscribed US$112 million Series C financing round. This significant milestone highlights the confidence investors…

Read MoreAdvanCell Closes Oversubscribed $112M Series C Funding
Cystic Fibrosis

Cystic Fibrosis Biotech Sionna Announces Groundbreaking $150M IPO for Treatment Development

Sionna Therapeutics Announces $150M IPO to Advance Cystic Fibrosis Drug Development Sionna Therapeutics, a Massachusetts-based biotechnology company specializing in cystic fibrosis (CF) treatments, has officially announced the terms of its highly anticipated initial public offering (IPO). The company aims to…

Read MoreCystic Fibrosis Biotech Sionna Announces Groundbreaking $150M IPO for Treatment Development

IMCAS 2025: Galderma Phase IIIb Data Show Rapid, Long-Lasting Benefits of Relfydess™

Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient satisfaction of RelabotulinumtoxinA (Relfydess™) for treating frown lines (glabellar lines).…

Read MoreIMCAS 2025: Galderma Phase IIIb Data Show Rapid, Long-Lasting Benefits of Relfydess™

KORU Medical Systems Partners on Phase III Clinical Trial for Innovative Nephrology Drug Indication

KORU Medical Systems Partners on Phase III Trial for Rare Renal Disorder Treatment, Expanding Its Reach in Subcutaneous Infusion Solutions KORU Medical Systems (NASDAQ: KRMD), a leading innovator in large-volume subcutaneous infusion solutions, has announced an exciting collaboration with a…

Read MoreKORU Medical Systems Partners on Phase III Clinical Trial for Innovative Nephrology Drug Indication

Ferrer Earns Recognition for Industry-Leading Ethics and Compliance Program

Ferrer Achieves Compliance Leader Verification™: A Testament to Excellence in Ethics and Corporate Responsibility In a significant milestone for ethical business practices, Ferrer, a global pharmaceutical company headquartered in Barcelona, has been awarded the prestigious Compliance Leader Verification™ by Ethisphere,…

Read MoreFerrer Earns Recognition for Industry-Leading Ethics and Compliance Program